Literature DB >> 30126955

Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.

Omamah Alfarisi1, Vidya Mave1,2, Sanjay Gaikwad3, Tushar Sahasrabudhe4, Geetha Ramachandran5, Hemanth Kumar5, Nikhil Gupte1,2, Vandana Kulkarni2, Sona Deshmukh2, Sachin Atre4, Swapnil Raskar2, Rahul Lokhande3, Madhusudan Barthwal4, Arjun Kakrani4, Sandy Chon1, Amita Gupta1,2, Jonathan E Golub1, Kelly E Dooley6.   

Abstract

Diabetes mellitus (DM) and tuberculosis (TB) are two common diseases with increasing geographic overlap and clinical interactions. The effect of DM and hemoglobin A1c (HbA1c) values on the pharmacokinetics (PK) and pharmacodynamics (PD) of anti-TB drugs remains poorly characterized. Newly diagnosed TB patients with and without DM starting fixed-dose, thrice-weekly treatment underwent sampling for PK assessments (predose and 0.5, 2, and 6 h postdose) during the intensive and continuation phases of treatment. The effect of DM and HbA1c values on the maximum concentration (C max) of rifampin, isoniazid, and pyrazinamide and the association between drug concentrations and microbiologic and clinical outcomes were assessed. Of 243 patients, 101 had DM. Univariate analysis showed significant reductions in the C max of pyrazinamide and isoniazid (but not rifampin) with DM or increasing HbA1c values. After adjusting for age, sex, and weight, DM was associated only with reduced pyrazinamide concentrations (adjusted geometric mean ratio = 0.74, P = 0.03). In adjusted Cox models, female gender (adjusted hazards ratio [aHR] = 1.75, P = 0.001), a lower smear grade with the Xpert assay (aHR = 1.40, P < 0.001), and the pyrazinamide C max (aHR = 0.99, P = 0.006) were independent predictors of sputum culture conversion to negative. Higher isoniazid or rifampin concentrations were associated with a faster time to culture conversion in patients with DM only. A pyrazinamide C max above the therapeutic target was associated with higher unfavorable outcomes (treatment failure, relapse, death) (odds ratio = 1.92, P = 0.04). DM and higher HbA1c values increased the risk of not achieving therapeutic targets for pyrazinamide (but not rifampin or isoniazid). Higher pyrazinamide concentrations, though, were associated with worse microbiologic and clinical outcomes. DM status also appeared to influence PK-PD relationships for isoniazid and rifampin.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  diabetes mellitus; pharmacodynamics; pharmacokinetics; tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 30126955      PMCID: PMC6201087          DOI: 10.1128/AAC.01383-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  69 in total

1.  Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies.

Authors:  Ranjeet Prasad Dash; Bhanuchander Ellendula; Milee Agarwal; Manish Nivsarkar
Journal:  Eur J Pharmacol       Date:  2015-10-10       Impact factor: 4.432

2.  Intermittent Versus Daily Pulmonary Tuberculosis Treatment Regimens: A Meta-Analysis.

Authors:  Samuel Kasozi; Justin Clark; Suhail A R Doi
Journal:  Clin Med Res       Date:  2015-06-08

3.  Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice.

Authors:  Shingo Matsumoto; Ichiro Koshiishi; Toyoshi Inoguchi; Hajime Nawata; Hideo Utsumi
Journal:  Free Radic Res       Date:  2003-07

4.  Small intestinal glucose absorption and duodenal motility in type 1 diabetes mellitus.

Authors:  C K Rayner; M P Schwartz; P S van Dam; W Renooij; M de Smet; M Horowitz; A J P M Smout; M Samsom
Journal:  Am J Gastroenterol       Date:  2002-12       Impact factor: 10.864

5.  Diabetic control and risk of tuberculosis: a cohort study.

Authors:  Chi C Leung; Tai H Lam; Wai M Chan; Wing W Yew; Kin S Ho; Gabriel M Leung; Wing S Law; Cheuk M Tam; Chi K Chan; Kwok C Chang
Journal:  Am J Epidemiol       Date:  2008-04-08       Impact factor: 4.897

6.  Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

Authors:  Sekai Chideya; Carla A Winston; Charles A Peloquin; William Z Bradford; Philip C Hopewell; Charles D Wells; Arthur L Reingold; Thomas A Kenyon; Themba L Moeti; Jordan W Tappero
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

7.  Higher susceptibility of type 1 diabetic rats to Mycobacterium tuberculosis infection.

Authors:  Isamu Sugawara; Satoru Mizuno
Journal:  Tohoku J Exp Med       Date:  2008-12       Impact factor: 1.848

8.  Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.

Authors:  A K Hemanth Kumar; T Kannan; V Chandrasekaran; V Sudha; A Vijayakumar; K Ramesh; J Lavanya; S Swaminathan; G Ramachandran
Journal:  Int J Tuberc Lung Dis       Date:  2016-09       Impact factor: 2.373

9.  Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications.

Authors:  R Court; M T Chirehwa; L Wiesner; B Wright; W Smythe; N Kramer; H McIlleron
Journal:  Int J Tuberc Lung Dis       Date:  2018-05-01       Impact factor: 2.373

10.  The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus.

Authors:  Ye-Jin Lee; Sung Koo Han; Ju Hee Park; Jung Kyu Lee; Deog Keom Kim; Hee Soon Chung; Eun Young Heo
Journal:  Korean J Intern Med       Date:  2018-03-16       Impact factor: 2.884

View more
  14 in total

1.  Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity.

Authors:  B G J Dekkers; O W Akkerman; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Whole genome sequencing analysis to evaluate the influence of T2DM on polymorphisms associated with drug resistance in M. tuberculosis.

Authors:  Gustavo Adolfo Bermudez-Hernández; Damián Eduardo Pérez-Martínez; Carlos Francisco Madrazo-Moya; Irving Cancino-Muñoz; Iñaki Comas; Roberto Zenteno-Cuevas
Journal:  BMC Genomics       Date:  2022-06-24       Impact factor: 4.547

3.  Whole Genome Sequencing Assessing Impact of Diabetes Mellitus on Tuberculosis Mutations and Type of Recurrence in India.

Authors:  Vidya Mave; Liang Chen; Uma Devi Ranganathan; Dileep Kadam; Vijay Vishwanathan; Rahul Lokhande; Siva Kumar S; Anju Kagal; Neeta N Pradhan; Shri Vijay Bala Yogendra Shivakumar; Mandar S Paradkar; Sona Deshmukh; Jeffrey A Tornheim; Hardy Kornfeld; Maha Farhat; Amita Gupta; Chandrasekaran Padmapriyadarsini; Nikhil Gupte; Jonathan E Golub; Barun Mathema; Barry N Kreiswirth
Journal:  Clin Infect Dis       Date:  2022-09-14       Impact factor: 20.999

4.  Epidemiology and Risk Factors of Delayed Sputum Smear Conversion in Malaysian Aborigines with Smear-Positive Pulmonary Tuberculosis.

Authors:  Muhammad Naim Ibrahim; Nik Rosmawati Nik Husain; Aziah Daud; Thilaka Chinnayah
Journal:  Int J Environ Res Public Health       Date:  2022-02-18       Impact factor: 3.390

Review 5.  Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.

Authors:  Tesemma Sileshi; Gosaye Mekonen; Eyasu Makonnen; Eleni Aklillu
Journal:  Pharmgenomics Pers Med       Date:  2022-06-04

Review 6.  Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression.

Authors:  Guillermo Cáceres; Rodrigo Calderon; Cesar Ugarte-Gil
Journal:  Ther Adv Infect Dis       Date:  2022-05-20

7.  Tuberculosis Relapse in the Epididymis After the Completion of Nine Months of Anti-Tuberculosis Chemotherapy in a Patient with Poorly Controlled Diabetes Mellitus.

Authors:  Chikako Ichikawa; Sho Tanaka; Masahiro Takubo; Masaru Kushimoto; Jin Ikeda; Katsuhiko Ogawa; Ichiro Tsujino; Yutaka Suzuki; Masanori Abe; Hisamitsu Ishihara; Midori Fujishiro
Journal:  Ther Clin Risk Manag       Date:  2021-05-25       Impact factor: 2.423

8.  Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus.

Authors:  Sarah C Mann; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Austin Saderup; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson; Jose R Castillo-Mancilla
Journal:  J Acquir Immune Defic Syndr       Date:  2020-12-01       Impact factor: 3.771

Review 9.  Diabetes-Associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia.

Authors:  Minh Dao Ngo; Stacey Bartlett; Katharina Ronacher
Journal:  Microorganisms       Date:  2021-11-02

10.  Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients.

Authors:  Charles M Mtabho; Hadija H Semvua; Jossy van den Boogaard; Constantine F Irongo; Martin J Boeree; Angela Colbers; David M Burger; Reinout van Crevel; Andre J A M van der Ven; Gibson S Kibiki; Alma Tostmann; Rob E Aarnoutse
Journal:  J Antimicrob Chemother       Date:  2019-12-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.